Albert G. White III Purchases 20,000 Shares of Evolus, Inc. (NASDAQ:EOLS) Stock

Evolus, Inc. (NASDAQ:EOLS - Get Free Report) Director Albert G. White III bought 20,000 shares of Evolus stock in a transaction dated Monday, June 9th. The stock was acquired at an average cost of $9.45 per share, with a total value of $189,000.00. Following the completion of the acquisition, the director now owns 50,378 shares of the company's stock, valued at $476,072.10. This represents a 65.84% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink.

Evolus Stock Performance

NASDAQ EOLS traded down $0.25 on Friday, hitting $9.93. 1,068,138 shares of the stock traded hands, compared to its average volume of 740,551. The business's fifty day moving average is $10.31 and its two-hundred day moving average is $11.80. Evolus, Inc. has a 12 month low of $8.67 and a 12 month high of $17.82. The firm has a market capitalization of $640.25 million, a price-to-earnings ratio of -10.91 and a beta of 1.00. The company has a debt-to-equity ratio of 20.58, a quick ratio of 2.23 and a current ratio of 2.47.

Hedge Funds Weigh In On Evolus

Institutional investors and hedge funds have recently bought and sold shares of the company. AlphaQuest LLC bought a new position in Evolus during the first quarter valued at $39,000. State of Wyoming boosted its holdings in shares of Evolus by 988.1% in the first quarter. State of Wyoming now owns 3,754 shares of the company's stock worth $45,000 after acquiring an additional 3,409 shares during the period. KBC Group NV bought a new position in shares of Evolus in the fourth quarter worth $49,000. IFP Advisors Inc boosted its holdings in shares of Evolus by 17,440.7% in the fourth quarter. IFP Advisors Inc now owns 4,736 shares of the company's stock worth $52,000 after acquiring an additional 4,709 shares during the period. Finally, KLP Kapitalforvaltning AS bought a new position in shares of Evolus in the fourth quarter worth $106,000. 90.69% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

EOLS has been the subject of several recent analyst reports. BTIG Research initiated coverage on Evolus in a report on Thursday, April 17th. They issued a "buy" rating and a $21.00 target price for the company. Barclays increased their price objective on Evolus from $22.00 to $25.00 and gave the company an "overweight" rating in a report on Wednesday, March 5th. HC Wainwright reissued a "buy" rating and set a $27.00 price objective on shares of Evolus in a report on Thursday, April 10th. Finally, Needham & Company LLC reissued a "buy" rating and set a $22.00 price objective on shares of Evolus in a report on Thursday, May 8th. Five research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company has a consensus rating of "Buy" and a consensus target price of $23.75.

About Evolus

Evolus, Inc, a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.